Treatment of chronic hepatitis B with telbivudine: Wise hepatologists needed in hepatitis B endemic countries where treatment options are limited

Liver International

Volumn 31, Issue 5, 2011, Pages 589-591

  Yurdaydin, Cihan ^a   Akarca, Ulus S ^b  

^a ANKARA UNIVERSITY   (Turkey)

^b EGE UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PEGINTERFERON; TELBIVUDINE; TENOFOVIR; VIRUS DNA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; EDITORIAL; ENDEMIC DISEASE; HEPATITIS B; HUMAN; LIVER CELL CARCINOMA; REIMBURSEMENT; SEROCONVERSION;

ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; DRUG SUBSTITUTION; ENDEMIC DISEASES; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; NUCLEOSIDES; PYRIMIDINONES; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 79953307445     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2010.02437.x     Document Type: Editorial

References (22)

1. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: 227-42.
2. Lok ASF, McMahon BJ. Chronic hepatitis B: update 2009. Available at
3. Woo G, Tomlinson G, Nishikawa Y, et al. Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses. Gastroenterology 2010; 139: 1218-29.
4. Van Nunen AB, Hansen BE, Suh DJ, et al. Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase. Gut 2003; 52: 420-4.
5. Reijnders JG, Perquin MJ, Zhang N, et al. Nucleos(t)ide analogues only induce temporary hepatitis e antigen seroconversion in most patients with chronic hepatitis B. Gastroenterology 2010; 139: 491-8.
6. Marcellin P, Piratvisuth T, Brunetto MR, et al. A finite course of peginterferon alfa-2a results in inactive chronic hepatitis B and HBsAg clearance 5 years pot-treatment in patients with HBeAg-negative disease: baseline characteristics and predictive factors of long-term response (abstr). Hepatology 2009; 50: 487A.
7. Buster EHCJ, Hansen BE, Lau GKK, et al. Factors that predict response of patients with hepatitis B e antigen - positive chronic hepatitis B to peginterferon-alfa. Gastroenterology 2009; 137: 2002-9.
8. Bonino F, Marcellin P, Lau GKK, et al. Predicting response to peginterferon alfa-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B. Gut 2007; 56: 699-705.
9. Lampertico P, Colombo M. HBeAg-negative chronic hepatitis B: why do I treat my patients with nucleos(t)ide analogs. Liver Int 2009; 29 (Suppl. 1): 130-2.
10. Coffin CS, Lee SS. Treatment of HBeAg-positive patients with nucleos/tide analogues. Liver Int 2009; 29 (Suppl. 1): 116-24.
11. Gane E, Wang Y, Liaw YF, et al. Efficacy and safety of prolonged 3-year telbivudine treatment in patients with chronic hepatitis B. Liver Int 2011; 31: 676-84.
12. Safadi R, Xie Q, Chen Y, et al. Efficacy of switching to telbivudine in chronic hepatitis B patients previously treated with lamivudine. Liver Int 2011; 31: 667-75.
13. Liaw YF. Antiviral therapy of chronic hepatitis B: opportunities and challenges in Asia. J Hepatol 2009; 51: 403-10.
14. Ferenci P, Fried M, Labrecque D, et al. World Gastroenterology Organisation Guideline. Hepatocellular carcinoma (HCC): a global perspective. J Gastrointestin Liver Dis 2010; 19: 311-7.
15. Hoofnagle JH. Therapy of hepatitis B. Unresolved issues and remaining challenges. AASLD 2010, Postgraduate Course Book, pp. 52-5
16. Zeuzem S, Gane E, Liaw YF, et al. Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B. J Hepatol 2009; 51: 11-20.
17. Keeffe EB, Zeuzem S, Koff RS, et al. Report of an international workshop: roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol 2007; 5: 890-97.
18. Heathcote EJ, Gane EJ, deMan RA, et al. Long term (4 year) efficacy and safety of tenofovir disoproxil fumarate treatment in HBeAg-positive patients with chronic hepatitis B (study 103): preliminary analysis (abstract). Hepatology 2010; 52: 556A.
19. Pan C, Tong MJ, Kowdley KV, et al. Long-term entecavir treatment for up to 5 years in Asian patients with HBeAg-positive nucleos(t)ide naïve chronic hepatitis B: results from ETV-022 and -901 (abstract). Hepatology 2010; 52: 557A.
20. Lampertico P, Vigano M, Manenti E, et al. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology 2007; 133: 835-42.
21. Idilman R, Kaymakoglu S, Önder FO, et al. A short-course of add-on adefovir dipivoxil treatment in lamivudine-resistant chronic hepatitis B. J Viral Hepat 2009; 16: 279-85.
22. Hadziyannis SJ, Vassilopoulos D. Hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2001; 34: 617-24.